Lineage Cell Number Of Employees vs. Debt To Equity
| BTX Stock | ILS 201.20 0.30 0.15% |
For Lineage Cell profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lineage Cell to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lineage Cell Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lineage Cell's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lineage Cell Therapeutics over time as well as its relative position and ranking within its peers.
Lineage |
Lineage Cell Therapeutics Debt To Equity vs. Number Of Employees Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lineage Cell's current stock value. Our valuation model uses many indicators to compare Lineage Cell value to that of its competitors to determine the firm's financial worth. Lineage Cell Therapeutics is rated below average in number of employees category among its peers. It also is rated below average in debt to equity category among its peers fabricating about 0.04 of Debt To Equity per Number Of Employees. The ratio of Number Of Employees to Debt To Equity for Lineage Cell Therapeutics is roughly 24.52 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Lineage Cell by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lineage Cell's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Lineage Number Of Employees vs. Competition
Lineage Cell Therapeutics is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 426. Lineage Cell retains roughly 76.0 in number of employees claiming about 18% of stocks in Biotechnology industry.
Lineage Debt To Equity vs. Number Of Employees
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Lineage Cell |
| = | 76 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Lineage Cell |
| = | 3.10 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Lineage Debt To Equity Comparison
Lineage Cell is rated fifth in debt to equity category among its peers.
Lineage Cell Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lineage Cell, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lineage Cell will eventually generate negative long term returns. The profitability progress is the general direction of Lineage Cell's change in net profit over the period of time. It can combine multiple indicators of Lineage Cell, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.
Lineage Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lineage Cell. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lineage Cell position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lineage Cell's important profitability drivers and their relationship over time.
Use Lineage Cell in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lineage Cell position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will appreciate offsetting losses from the drop in the long position's value.Lineage Cell Pair Trading
Lineage Cell Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Lineage Cell could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lineage Cell when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lineage Cell - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lineage Cell Therapeutics to buy it.
The correlation of Lineage Cell is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lineage Cell moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lineage Cell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lineage Cell can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lineage Cell position
In addition to having Lineage Cell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Municipals ETFs Thematic Idea Now
Broad Municipals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Municipals ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Municipals ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Trending Equities. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
To fully project Lineage Cell's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lineage Cell Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lineage Cell's income statement, its balance sheet, and the statement of cash flows.